Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies

Blood

Volumn 121, Issue 5, 2013, Pages 849-857

  Bartolomeo, Paolo Di ^a   Santarone, Stella ^a   De Angelis, Gottardo ^b   Picardi, Alessandra ^b   Cudillo, Laura ^b   Cerretti, Raffaella ^b   Adorno, Gaspare ^b   Angelini, Stefano ^b   Andreani, Marco ^c   De Felice, Lidia ^d   Rapanotti, Maria Cristina ^b   Sarmati, Loredana ^b   Bavaro, Pasqua ^a   Papalinetti, Gabriele ^a   Di Nicola, Marta ^e   Papola, Franco ^f   Montanari, Mauro ^g   Nagler, Arnon ^h   Arcese, William ^b,c  

^a SPIRITO SANTO HOSPITAL   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF CHIETI   (Italy)

^f SAN SALVATORE HOSPITAL   (Italy)

^g OSPEDALI RIUNITI   (Italy)

^h SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BASILIXIMAB; BUSULFAN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; FLUCONAZOLE; FLUDARABINE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CELLULAR PARAMETERS; CHILD; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; FEASIBILITY STUDY; FEMALE; HAPLOIDY; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NEUTROPHIL ENGRAFTMENT; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PLASMA CELL LEUKEMIA; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; SINGLE DRUG DOSE; VEIN OCCLUSION;

EID: 84873558649     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-08-453399     Document Type: Article

References (48)

1. Petersdorf EW, The World Marrow Donor Association: 20 years of international collaboration for the support of unrelated donor and cord blood hematopoietic cell transplantation. Bone Marrow Transplant. 2010;45(5): 807-810.
2. Foeken LM, Green A, Hurley CK, et al. Monitoring the international use of unrelated donors for transplantation: the WMDAannual reports. Bone Marrow Transplant. 2010;45(5): 811-818.
3. Bone Marrow Donors Worldwide, Statistics: Stem cell donor registries. http://www.bmdw.org. Accessed June 30, 2012.
4. Ballen KK, Spitzer TR. The great debate: haploidentical or cord blood transplant. Bone Marrow Transplant. 2011;46(3):323-329.
5. Ballen KK, Koreth J, Chen Y-B, Dey BR, Spitzer TR. Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood. 2012;119(9):1972-1980.
6. Gluckman E, Rocha V. Cord blood transplantation: state of the art. Haematologica. 2009;94(4): 451-454.
7. Bertaina A, Bernardo ME, Caniglia M, et al. Cord blood transplantation in children with haematological malignancies. Best Pract Res Clin Haematol. 2010;23(2):189-196.
8. Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med. 2001;344(24):1815-1822. (Pubitemid 32538694)
9. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004;351(22):2276-2285. (Pubitemid 39552743)
10. Arcese W, Rocha V, Labopin M, et al. Unrelated cord blood transplant in adults with hematological malignancies. Haematologica. 2006;91(2):223-30.
11. Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukemia: a comparison study. Lancet. 2007;369(9577): 1947-1954. (Pubitemid 46874578)
12. Eapen M, Rocha V, Sanz G, et al., Effect of graft source on unrelated donor haemopoietic stemcell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010;11(7):653-660.
13. Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of two partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood. 2005; 105(3):1343-1347. (Pubitemid 40170912)
14. Tung SS, Parmar S, Robinson SN, de Lima M, Shpall EJ, Ex vivo expansion of umbilical cord blood for transplantation. Best Pract Res Clin Haematol. 2010;23(2):245-257.
15. Frassoni N, Gualandi F, Modesta M, et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol. 2008;9(9):831-839.
16. Fernández MN. Improving the outcome of cord blood transplantation: use of mobilized HSC and other cells from third party donors. Br J Haematol. 2009;147(2):161-176.
17. Aversa F. Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States. Bone Marrow Transplant. 2008;41(5):473-481. (Pubitemid 351386712)
18. Aversa F, Tabilio A, Velardi A, et al. Treatment of high risk acute leukemia with T-cell depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998; 339(17):1186-1193. (Pubitemid 28482127)
19. Aversa F, Terenzi A, Tabilio A, et al. Full-haplotype mismatched hematopoietic stem cell transplantation: a phase II study in patients with acute leukemia at high risk or relapse. J Clin Oncol. 2005;23(15):3447-3454.
20. Ji S-Q, Chen H-R, Yan H-M, et al. Anti-CD25 monoclonal antibody (basiliximab) for prevention of graft-versus-host disease after haploidentical bone marrow transplantation for hematological malignancies. Bone Marrow Transplant. 2005; 36(4):349-354. (Pubitemid 41195169)
21. Lu D-P, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107(8):3065-3073.
22. Luznik L, O'Donnell PV, Symons HJ, et al. HLA haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641-650. (Pubitemid 351664058)
23. Huang X-J, Liu D-H, Liu K-Y, et al. Treatment of Acute Leukemia with Unmanipulated HLA Mismatched/Haploidentical Blood and Bone Marrow Transplantation. Biol Blood Marrow Transplant. 2009;15(2):257-265.
24. Brunstein CG, Fuchs EJ, Carter SJ, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118(2):282-288.
25. Sanz J, Boluda JCH, Martín C, et al. Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transplantation. 2012;47(10):1287-1293.
26. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295-304.
27. Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GvHD grading. Bone Marrow Transplant. 1995;15(6):825-828.
28. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69(2):204-217. (Pubitemid 10036817)
29. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
30. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50(3):163-170.
31. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706. (Pubitemid 29126745)
32. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16(3):1141-54.
33. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B. 1972;34(2):187-220.
34. Fine JP, Gray RJ. A proportional hazards model for subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
35. Powles RL, Morgenstern GR, Kay HE, et al. Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet. 1983;1(8325):612-615. (Pubitemid 13152341)
36. Beatty PG, Clift RA,. Mickelson EM, Nisperos BB, Flournoy N, Martin PJ, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985;313(13):765-771. (Pubitemid 15232310)
37. Anasetti C, Amos D, Beatty P, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989;320(4):197-204. (Pubitemid 19034144)
38. Rizzieri DA, Koh LP, Long GD, et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol. 2007;25(6):690-697. (Pubitemid 350002925)
39. Ciceri F, Labopin M, Aversa F, et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood. 2008;112(9): 3574-3581.
40. Davies JK., Gribben JG, Brennan LL, Yuk D, Nadler LM, Guinan EC, Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies. Blood. 2008;112(6):2232-2241.
41. Bethge WA, Faul C, Bornhauser M, et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: An update. Blood Cells Mol Dis. 2008;40(1):13-19. (Pubitemid 350192298)
42. Grosso D, Carabasi M, Filicko-O'Hara J, et al. A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing. Blood. 2011; 118(17):4732-4739.
43. Shier LR, Schultz KR, Imren S, et al. Differential effects of granulocyte colony-stimulating factor on marrow- and blood-derived hematopoietic and immune cell populations in healthy human donors. Biol Blood Marrow Transplant. 2004;10(7): 624-634. (Pubitemid 39157828)
44. Tayebi H, Kuttler F, Saas P, et al. Effect of granulocyte colony-stimulating factor mobilization on phenotypical and functional properties of immune cells. Exp Hematol. 2001;29(4): 458-470. (Pubitemid 32297670)
45. Jun HX, Jun CY, Yu ZX. In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Haematologica. 2004;89(12):1517-1524.
46. Jun HX, Jun CY, Yu ZX. A direct comparison of immunological characteristics of granulocyte colony-stimulating factor (G-CSF)-primed bone marrow grafts and G-CSF-mobilized peripheral blood grafts. Haematologica. 2005;90(5):715-716. (Pubitemid 40780905)
47. Chang Y-J, Zhao X-Y, Huo M-R, Huang X-J. Expression profiles of adhesion molecules on naïve T cells in bone marrow grafts of healthy donors treated with granulocyte colony-stimulating factor. Transpl Immunol. 2009;21(4): 228-233.
48. Morton J, Hutchins C, Durrant S. Granulocytecolony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versushost disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood. 2001;98(12):3186-3191.